Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) CEO Jeffrey A. Meckler bought 9,600 shares of the company's stock in a transaction that occurred on Monday, November 21st. The stock was purchased at an average price of $1.90 per share, for a total transaction of $18,240.00. Following the transaction, the chief executive officer now owns 75,374 shares of the company's stock, valued at $143,210.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Indaptus Therapeutics Stock Performance

Indaptus Therapeutics stock opened at $1.80 on Friday. Indaptus Therapeutics, Inc. has a 12 month low of $1.64 and a 12 month high of $7.10. The stock's 50 day simple moving average is $2.00 and its two-hundred day simple moving average is $2.43.

Institutional Investors Weigh In On Indaptus Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $41,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $78,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the 2nd quarter worth approximately $51,000. Vanguard Group Inc. boosted its position in Indaptus Therapeutics by 18.7% in the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after purchasing an additional 38,216 shares in the last quarter. Finally, Strategy Asset Managers LLC purchased a new stake in Indaptus Therapeutics in the 3rd quarter worth approximately $120,000. Hedge funds and other institutional investors own 19.25% of the company's stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.

Further Reading

• Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
• Microsoft Shares: Is it Time to Back Up the Truck?
• Institutional Support for Analog Devices Remains High
• Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
• Is the 60/40 Portfolio Mix Still in Vogue?
• Three CBD Stocks to Dominate a Budding Industry

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.